Botulinum neurotoxin A enhances the analgesic effects on inflammatory pain and antagonizes tolerance induced by morphine in mice

Brain, Behavior, and Immunity

Volumn 26, Issue 3, 2012, Pages 489-499

  Vacca, Valentina ^a   Marinelli, Sara ^a   Eleuteri, Cecilia ^a   Luvisetto, Siro ^a   Pavone, Flaminia ^a  

^a CNR   (Italy)

Author keywords

Behavior; Botulinum neurotoxins; Formalin pain; Glial cells; Immunofluorescence; Morphine tolerance; Opioid; Spinal cord

Indexed keywords

BOTULINUM TOXIN A; FORMALDEHYDE; MORPHINE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SPINAL CORD;

ANALGESICS, OPIOID; ANIMALS; ASTROCYTES; BOTULINUM TOXINS, TYPE A; DRUG SYNERGISM; DRUG TOLERANCE; INFLAMMATION; MALE; MICE; MORPHINE; NEUROMUSCULAR AGENTS; PAIN; PAIN MEASUREMENT; SPINAL CORD;

EID: 84857189855     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.01.002     Document Type: Article

References (83)

1. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., Caleo M. Long distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 2008, 28:3689-3696.
2. Araque A., Li N., Doyle R.T., Haydon P.G. SNARE protein-dependent glutamate release from astrocytes. J. Neurosci. 2000, 20:666-673.
3. Ashkenazi A. Botulinum toxin type a for chronic migraine. Curr. Neurol. Neurosci. Rep. 2010, 10:140-146.
4. Bach-Rojecky L., Lacković Z. Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat. Med. J. 2005, 46:201-208.
5. Bach-Rojecky L., Relja M., Lacković Z. Botulinum toxin type A in experimental neuropathic pain. J. Neural. Trans. 2005, 112:215-219.
6. Bach-Rojecky L., Dominis M., Lacković Z. Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundam. Clin. Pharmacol. 2008, 22:503-509.
7. Bach-Rojecky L., Lacković Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol. Biochem. Behav. 2009, 94:234-238.
8. Benarroch E.E. Central neuron-glia interactions and neuropathic pain: overview of recent concepts and clinical implications. Neurology 2010, 75:273-278.
9. Blasi J., Binz T., Yamasaki S., Link E., Niemann H., Jahn R. Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins. J. Physiol. (Paris) 1994, 88:235-241.
10. Bohn L.M., Gainetdinov R.R., Lin F.T., Lefkowitz R.J., Caron M.G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000, 408:720-723.
11. Carmichael N.M., Dostrovsky J.O., Charlton M.P. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain 2010, 149:316-324.
12. Chen Y., Sommer C. The role of Mitogen-Activated Protein Kinase (MAPK) in morphine tolerance and dependence. Mol. Neurobiol. 2009, 40:101-107.
13. Chu J., Zheng H., Loh H.H., Law P.Y. Morphine-induced mu-opioid receptor rapid desensitization is independent of receptor phosphorylation and beta-arrestins. Cell Signal. 2008, 20:1616-1624.
14. Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125-133.
15. Cui Y., Chen Y., Zhi J.-L., Guo R.-X., Feng J.-Q., Chen P.-X. Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res. 2006, 1069:235-243.
16. Cui Y., Liao X.X., Liu W., Guo R.X., Wu Z.Z., Zhao C.M., Chen P.X., Feng J.Q. A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav. Immun. 2008, 22:114-123.
17. Dang V.C., Chieng B., Azriel Y., Christie M.J. Cellular morphine tolerance produced by ß-arrestin-2-dependent impairment of μ-opioid receptor resensitization. J. Neurosci. 2011, 31:7122-7130.
18. DeLeo J.A., Tanga F.Y., Tawfik V.L. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 2004, 10:40-52.
19. DeLeo J.A., Tawfik V.L., LaCroix-Fralish M.L. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain 2006, 122:17-21.
20. Dolly J.O., Aoki K.R. The structure and mode of action of different botulinum toxins. Eur. J. Neurol. 2006, 13(Suppl. 4):1-9.
21. Durham P.L., Cady R., Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35-43.
22. Favre-Guilmard C., Auguet M., Chabrier P.E. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur. J. Pharmacol. 2009, 617:48-53.
23. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., Smith L., Aoki K.R., Dolly J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 2003, 278:1363-1371.
24. Garzon J., Rodriguez-Munoz M., Sànchez-Blazquez P. Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery?. Curr. Drug Abuse Rev. 2008, 1:222-238.
25. Gazerani P., Au S., Dong X., Kumar U., Arendt-Nielsen L., Cairns B.E. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain 2010, 151:606-616.
26. He L., Fong J., von Zastrow M., Whistler J.L. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 2002, 108:271-282.
27. Hou Y.P., Zhang Y.P., Song Y.F., Zhu C.M., Wang Y.C., Xie G.L. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can. J. Physiol. Pharmacol. 2007, 85:209-214.
28. Hua X.Y., Svensson C.I., Matsui T., Fitzsimmons B., Yaksh T.L., Webb M. Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur. J. Neurosci. 2005, 22:2431-2440.
29. Inoue M., Mishina M., Ueda H. Locus-specific rescue of GluRepsilon1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. J. Neurosci. 2003, 23:6529-6536.
30. Jabbari B. Botulinum neurotoxins in the treatment of refractory pain. Nature Clin. Pract. Neurol. 2008, 4:676-685.
31. Ji R.R., Samad T.A., Jin S.X., Schmoll R., Woolf C.J. P38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36:57-68.
32. Kim S.Y., Bae J.C., Kim J.Y., Lee H.L., Lee K.M., Kim D.S., Cho H.J. Activation of p38 MAPK in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. NeuroReport 2002, 13:2483-2486.
33. Lucioni A., Bales G.T., Lotan T.L., McGehee D.S., Cook S.P., Rapp D.E. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. Br. J. Urol. Int. 2008, 101:366-370.
34. Lutfy K., Shen K.Z., Woodward R.M., Weber E. Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. Brain Res. 1996, 731:171-181.
35. Luvisetto S., Rossetto O., Montecucco C., Pavone F. Toxicity of botulinum neurotoxins in central nervous system in mice. Toxicon 2003, 4:475-481.
36. Luvisetto S., Marinelli S., Lucchetti F., Marchi F., Cobianchi S., Rossetto O., Montecucco C., Pavone F. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain. Res. 2006, 1082:124-131.
37. Luvisetto S., Marinelli S., Cobianchi S., Pavone F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007, 145:1-4.
38. Mao J., Price D.D., Mayer D.J. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J. Neurosci. 1994, 14:2301-2312.
39. Mao J., Sung B., Ji R.R., Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J. Neurosci. 2002, 22:8312-8323.
40. Marie N., Aguila B., Allouche S. Tracking the opioid receptors on the way of desensitization. Cell Signal. 2006, 18:1815-1833.
41. Marinelli S., Luvisetto S., Cobianchi S., Makuch W., Obara I., Mezzaroma E., Caruso M., Straface E., Przewlocka B., Pavone F. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience 2010, 171:316-328.
42. Martini L., Whistler J.L. The role of μ opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr. Opin. Neurobiol. 2007, 17:556-564.
43. Matak I., Bach-Rojecky L., Filipović B., Lacković Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011, 186:201-207.
44. Mayer D.J., Mao J., Holt J., Price D.D. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. U S A 1999, 96:7731-7736.
45. McMahon H.T., Foran P., Dolly J.O., Verhage M., Wiegant V.M., Nicholls D.G. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J. Biol. Chem. 1992, 267:21338-21343.
46. McMahon S.B., Malcangio M. Current challenges in glia-pain biology. Neuron 2009, 64:46-54.
47. Meng J., Wang J., Lawrence G., Dolly J.O. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J. Cell. Sci. 2007, 120:2864-2874.
48. Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol. Rep. 2008, 60:297-307.
49. Mika J., Wawrzczak-Bargiela A., Osikowicz M., Makuch W., Przewlocka B. Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain Behav Immun. 2009, 23(1):75-84.
50. Mika J., Rojewska E., Makuch W., Korostynski M., Luvisetto S., Marinelli S., Pavone F., Przewlocka B. The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience 2011, 175:358-366.
51. Montecucco C., Rossetto O., Schiavo G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 2004, 12:442-446.
52. Montecucco C., Schiavo G., Pantano S. SNARE complexes and neuroexocytosis: how many, how close?. Trends Biochem. Sci. 2005, 30:367-372.
53. O'Callaghan J.P., Miller D.B. Spinal glia and chronic pain. Metabolism 2010, 59(Suppl 1):S21-S26.
54. Ossipov M.H., Lai J., King T., Vanderah T.W., Malan T.P., Hruby V.J., Porreca F. Antinociceptive and nociceptive actions of opioids. J. Neurobiol. 2004, 61:126-148.
55. Park H.J., Lee Y., Lee J., Park C., Moon D.E. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesth. 2006, 53:470-477.
56. Pavone F., Luvisetto S., Marinelli S., Straface E., Fabbri A., Falzano L., Fiorentini C., Malorni W. The Rac GTPase-activating bacterial protein toxin CNF1 induces analgesia up-regulating muopioid receptors. Pain 2009, 145:219-229.
57. Pavone F., Luvisetto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins 2010, 2:2890-2913.
58. Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem. Pharmacol. 2000, 59:1403-1406.
59. Qin M., Wang J.J., Cao R., Zhang H., Duan L., Gao B., Xiong Y.F., Chen L.W., Rao Z.R. The lumbar spinal cord glial cells actively modulate subcutaneous formalin induced hyperalgesia in the rat. Neurosci. Res. 2006, 55:442-450.
60. Raghavendra V., Rutkowski M.D., DeLeo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. 2002, 22:9980-9989.
61. Raghavendra V., Tanga F.Y., DeLeo J.A. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 2004, 29(2):327-334.
62. Ren K., Dubner R. Interactions between the immune and nervous systems in pain. Nature Med. 2010, 16:1267-1276.
63. Rossetto O., Seveso M., Caccin P., Schiavo G., Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 2001, 39:27-41.
64. Schiavo G., Rossetto O., Catsicas S., Polverino de Laureto P., DasGupta B.R., Benfenati F., Montecucco C. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J. Biol. Chem. 1993, 268:23784-23787.
65. Song P., Zhao Z.Q. The involvement of glial cells in the development of morphine tolerance. Neurosci. Res. 2001, 39:281-286.
66. Sorkin L.S., Boyle D.L., Hammaker D., Herman D.S., Vail E., Firestein G.S. MKK3, an upstream activator of p38, contributes to formalin phase 2 and late allodynia in mice. Neuroscience 2009, 162:462-471.
67. Svensson C.I., Marsala M., Westerlund A., Calcutt N.A., Campana W.M., Freshwater J.D., Catalano R., Feng Y., Protter A.A., Scott B., Yaksh T.L. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J. Neurochem. 2003, 86:1534-1544.
68. Svensson C.I., Brodin E. Spinal astrocytes in pain processing: non-neuronal cells as therapeutic targets. Mol. Interv. 2010, 10:25-38.
69. Sweitzer S.M., Colburn R.W., Rutkowski M., DeLeo J.A. Acute peripheral inflammation induces moderate glial activation and spinal IL-1β expression that correlates with pain behavior in the rat. Brain Res. 1999, 829:209-221.
70. Tawfik V.L., DeLeo J.A. The role of astrocytes in the modulation of pain. Synaptic Plasticity in Pain 2009, 387-401. Springer Science+Business Media, LLC. M. Malcangio (Ed.).
71. Taylor D.A., Fleming W.W. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J. Pharmacol. Exp. Ther. 2001, 297:11-18.
72. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991, 251:85-87.
73. Ueda H., Inoue M., Matsumoto T. Protein kinase C-mediated inhibition of mu-opioid receptor internalization and its involvement in the development of acute tolerance to peripheral muagonist analgesia. J. Neurosci. 2001, 21:2967-2973.
74. Ueda H., Ueda M. Mechanisms underlying morphine analgesic tolerance and dependence. Front. Biosci. 2009, 14:5260-5272.
75. Wang Z.J., Wang L.X. Phosphorylation: a molecular switch in opioid tolerance. Life Sci. 2006, 79:1681-1691.
76. Wang Z., Ma W., Chabot J.G., Quirion R. Calcitonin gene-related peptide as a regulator of neuronal CaMKII-CREB, microglial p38-NFκB and astroglial ERK-Stat1/3 cascades mediating the development of tolerance to morphine-induced analgesia. Pain 2010, 151:194-205.
77. Watkins L.R., Milligan E.D., Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001, 24:450-455.
78. Watkins L.R., Hutchinson M.R., Johnston I.N., Maier S.F. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. 2005, 28:661-669.
79. Watkins L.R., Hutchinson M.R., Rice K.R., Maier S.F. The "Toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharm. Sci. 2009, 30:581-591.
80. Xiao L., Mackey S., Hui H., Xong D., Zhang Q., Zhang D. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med. 2010, 11:1827-1833.
81. Xu M., Bruchas M.R., Ippolito D.L., Gendron L., Chavkin C. Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by k opioid activation of p38 mitogen activated protein kinase. J. Neurosci. 2007, 27:2570-2581.
82. Zhang H., Xin W., Dougherty P.M. Synaptically evoked glutamate transporter currents in spinal dorsal horn astrocytes. Mol. Pain 2009, 5:1-11.
83. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.